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Background: Human gliomas pose significant morbidity and mortality to those afflicted by them, and currently
there are no curative treatment modalities available for these highly invasive tumours.
Methods: With the approval from the human ethics committee, patients diagnosed with brain tumour (glioma)
were recruited for this study. At the time of surgical resection, freshly resected tumour as well as ‘peri-tumour’
tissue were taken directly from theatre to the laboratory and were successfully cultured. Confocal fluorescence
microscopy techniques and immunohistochemistry were used for characterization of human glioma cultures. Dye
uptake experiments and confocal microscopy were utilized for P2X7 receptor (P2X7R) pore activity.
Results: We reveal human glioma cultures to contain microglia in close association with glioma (tumour) cells. Both
glioma cells and microglia were found to express the purinergic, ATP sensing, P2X7R. P2X7R protein expression was
increased in microglia derived from tumour when compared to ‘peri-tumour’ tissue. The pore capacity of P2X7R in
tumour-associated microglia was functional, as evidenced by dye uptake experiments. Importantly, inhibition of
P2X7R with the synthetic antagonist, brilliant blue G (BBG) resulted in a significant decrease in the number of
glioma cells in culture.
Conclusions: P2X7R was found to be over-expressed in grade IV human gliomas and its pore capacity was
functional. Antagonism of P2X7R with BBG resulted in a decrease in tumour cell number. This identifies P2X7R as a
promising therapeutic target to combat human glioma proliferation.
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Gliomas are the most common type of intrinsic brain
tumour and a major cause of morbidity and mortality for
those afflicted by these highly invasive tumours. The major-
ity of adult gliomas are high-grade astrocytomas, compris-
ing grade 3 anaplastic astrocytoma (AA) and grade 4
glioblastoma multiforme (GBM) [1]. In addition to tumour
cells, gliomas contain microglia, which are known to
contribute to the tumour mass [2]. Microglia are the
immunocompetent cells of the central nervous system.
Under normal conditions microglia assume a quiescent/
resting (ramified) phenotype, but in the setting of brain
injury or neoplasia microglia become activated [2].* Correspondence: davidaw@unimelb.edu.au
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unless otherwise stated.Activated microglia are capable of releasing various im-
munomodulatory molecules that could alter the course
of tumourogenesis [3]. The mechanisms controlling the
transition from ramified to activated microglia are not
fully understood. We have recently shown that the puri-
nergic receptor, P2X7R, is involved in this transition [4].
The P2X7R is an ATP sensing receptor expressed in
cells of haemopoeitic and immunological origin such as
monocytes, macrophages, mast cells and microglia [5].
Increased P2X7R expression in microglia in the brain
has been reported in the setting of Alzheimer’s disease
[6,7], multiple sclerosis [8], brain ischemia [9] and spinal
cord injury [10]. Pharmacological blockade of P2X7R has
been shown to be neuroprotective in an animal model of
Alzheimer’s disease [6], enhance recovery in animal models
of spinal cord injury [10], and reduce neuroinflammation in
an experimental model of autoimmune encephalomyelitistd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of cancers, including those of the breast [12], prostate [12],
thyroid [13] pancreas [14], melanoma [15,16], chronic
lymphocytic leukemia [17], human neuroblastoma [18], the
rat C6 glioma model, and more recently human glioblast-
oma [19]. However, the role that P2X7R plays in the biology
of brain neoplasms is unknown.
The P2X7R has dual ionic conductance states. Transient
stimulation with agonist (most commonly ATP) opens a
P2X7R channel permeable to small cations, whereas sus-
tained agonist stimulation leads to a pore state permeable
to moieties of up to 900 Da [20,21]. The P2X7R pore ac-
tivity has been most commonly associated with conse-
quent cell death, apoptosis or cytolysis [20-23]. Recently,
we showed that in transfected rat primary hippocampal
neuron glia mixed cultures over-expression of P2X7R was
sufficient to induce microglial activation and proliferation
[4]. The trophic effects observed were dependant on
P2X7R pore activity (not channel), and there was no evi-
dence of P2X7R-induced cell death.
Whether P2X7R has a similar action in the setting of
human brain tumours is not known. Previous studies
have raised questions about the fundamental biological
role of P2X7R in the setting of cancer and cell trophism.
To explain the over-expression of a purported ‘cytolytic’
receptor in settings of cell trophism, some have suggested
that the receptor must therefore be ‘non-functional’ to
allow trophism rather than cell death [24]. It has also been
argued that in the setting of cancer/cell trophism P2X7R
is fully functional (intact channel and pore conductance)
and it indeed serves a homeostatic anti-tumour function
designed to have pro-apoptotic effects to deal with the
growing tumour burden [12]. In contrast some studies
have shown no evidence of P2X7R-mediated apoptosis,
and attribute the trophism/tumour growth to P2X7R
function itself [18].
In this study, we reveal increased P2X7R protein ex-
pression in microglia cultured from human brain
tumour versus ‘peri-tumour’ (region of macroscopically
normal brain surrounding the frank tumour). Pore ac-
tivity was evident in microglia, indicative of a normally
functioning receptor. These observations are also highly
supportive of a trophic rather than cell killing role for
P2X7R pore. Importantly, total inhibition of P2X7R ac-
tivity (channel and pore conductances) with brilliant
blue G (BBG) reduced the number of tumour cells in
culture. The results from this study identify P2X7R as a
potential anti-tumour therapeutic target.
Methods
Human tumour and peri-tumour cultures
Protocols for obtaining and handling human brain tis-
sue were reviewed and approved by the Human Research
Ethics Committee of the Royal Melbourne Hospital,Victoria, Australia. Written informed consent to study
brain tumour/‘peri-tumour’ tissue excised during tumour
surgery was obtained from patients prior to the operation.
Tumour tissue was obtained during routine tumour resec-
tion/debulking, and where safe ‘peri-tumour’ was obtained
during the same operation. The ‘peri-tumour’ tissue com-
prised macroscopically normal brain adjacent to the
tumour, which required removal for surgical access. Tissue
was received by direct explant from the operating room
and placed into sterile containers. Immediately after, the
samples were taken to the laboratory and in the laminar
flow hood (PC2 laboratory), the tissue was finely chopped.
The respective tumour and ‘peri-tumour’ pieces were
placed in an enzyme solution containing Papain (200
units; Sigma Aldrich) for 35 minutes at 37°C. The tissue
was washed 3 times to remove all traces of papain, and the
mixture was triturated to obtain a single cell suspension.
The cells were plated into 12 well plates containing 18 mm
Poly-D-lysine (Sigma) coated coverslips (SDR Clinical
Technology) at a density of 1.8 × 105 cells/well. Cultures
were maintained in Minimum Essential Medium (Gibco,
Invitrogen) with the following supplements: 1 mM glucose,
Penicillin-Streptomycin (5000 units/ml), 10% heat inacti-
vated Fetal Bovine Serum (GIBCO, Invitrogen), MITO+
™ Serum Extender (Becton Dickinson), and 2 mM L-glu-
tamine (GIBCO, Invitrogen). Cells were cultured at 37°C in
a humidified incubator of 5% CO2/95% O2. All cultures
were from grade IV (histological criteria) gliomas as diag-
nosed post-hoc after the removal of the tumour.
Immunohistochemistry
Human tumour and ‘peri-tumour’ cultures were fixed in a
solution of acetone and methanol (1:1), at −20°C. After fix-
ation, the cells were washed once with phosphate-buffered
saline (PBS), and non-specific protein binding sites were
blocked with 2% Bovine Serum Albumin (Sigma) for 45 mi-
nutes at 37°C. The following primary antibodies were used:
rabbit anti-GFAP (glial fibrillary acidic protein) primary
antibody (final dilution of 1:400; a kind gift from Professor
Jennifer Berka (Department of Immunology, Monash
University, Melbourne, Australia), isolectin GS-IB4 from
Griffonia simplicifolia, Alexa Fluor® 594 conjugate (final
dilution of 1:100; Molecular Probes), goat anti P2X7R
antibody (y-14; final dilution 1:100; Quantum Scien-
tific). Primary antibodies were made up in PBS, with 1%
Triton-X100 for permeabilization, and were incubated
overnight at 4°C. After three, 5 minute washes in PBS,
the cells were incubated with the relevant secondary
antibodies: Alexa Fluor® 488 (final dilution: 1:200; Mo-
lecular Probes) or Texas Red® X (final dilution: 1:200;
Molecular Probes). All secondary antibodies were incu-
bated overnight at 4°C. After three, 5 minute washes in
PBS, the samples were mounted with DAKO Fluores-
cent Mounting Medium. No staining was detected in
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preparations were counter labelled with DAPI nuclear
stain (5 μM; Molecular Probes).
Confocal microscopy
Human tumour and ‘peri-tumour’ cultures were viewed
with a Zeiss LSM 510 META multiphoton/confocal micro-
scope equipped with 488 nm argon, 543 and 633 nm Green
and Red Helium/Neon and 800 nm Chameleon lasers. Im-
ages were acquired with a 40× IR-Achromat (N.A. 0.80),
water immersion objective. For most experiments samples
were simultaneously stained with two or three fluorescent
probes, with dual or triple emission achieved through ap-
propriately selected emission filters, or by defining emission
ranges following prior acquisition of lambda emission pro-
files for each probe individually. Images were analyzed
using MetaMorph (Universal Imaging Corporation®) soft-
ware for assessment of cell number. For live cell imaging,
the cells were bathed in HEPES buffer (mM: NaCl 135, KCl
5, HEPES 10, Glucose 10, CaCl2 1, MgCl2 pH: 7.4) at room
temperature (~25°C).
P2X7R pore assay
We measured the degree of P2X7R pore activity inher-
ent in the culture environment in the absence of any ex-
ogenous pharmacological stimulus (designated as a pore
‘snap-shot’ experiment). At 7 days post culturing, the
cells were exposed to 5 μM of YOPRO-1 (345 kD; Mo-
lecular Probes) nuclear dye for 30 minutes. The cultures
were then immediately fixed, and mounted for confocal
imaging to assess the presence of pores by measuring
YOPRO-1 intensity of cell nuclei. To confirm that the
response observed was P2X7R specific, some human gli-
oma cultures were pre-exposed to oxidized ATP, a spe-
cific and irreversible antagonist of P2X7R [25]. Oxidized
ATP (250 μM) was applied 2.5 hours prior to YOPRO-1
application. Thereafter, the cells were washed once in
PBS, then immediately fixed, and mounted for confocal
imaging to assess the presence of pores by measuring
ethidium+ intensity of cell nuclei.
BBG experiments
Prior data from animal studies have revealed that BBG
administration protocols that resulted in average tissue
concentrations of 9.94-43.59 μM BBG over 3 consecu-
tive days were effective in reducing microglial activation
and enhancing recovery after spinal cord injury in rats
[26]. We used the more conservative BBG concentra-
tion of 7 μM to treat human glioma cultures at day 3
and 5 post culturing. The cultures were left in the pres-
ence of the BBG until day 10 post culture. By day 3
tumour and ‘peri-tumour’ cultured cells settled down
for adherence to poly-D-lysine coated coverslips, while
day 5 was routinely chosen as the day to replenish theculture medium. Thereafter, the cultures were fixed
with a solution of acetone:methanol (50:50), and proc-
essed for immunohistochemistry as described above.
Results
Morphological and cellular characteristics of human
gliomas in culture
We were able to successfully grow human tumour (n = 10
patients) and ‘peri-tumour’ cultures (n = 10 patients).
Figure 1 shows human glioma cultures after 7 days of
culturing, and illustrates extensive arrays of tumour
cells (GFAP positive) dispersed throughout the culture
environment. Tumour cells were found to cluster/aggre-
gate forming a densely packed arrangement (Figure 1A,C).
Within each cluster there were highly pleomorphic cells
with multiple nuclei (Figure 1A). This aggregative capacity
was absent from cultures derived from ‘peri-tumour’ tis-
sue (n = 4) peri-tumour cultures).
Microglia infiltrated the clusters of tumour cells, with
microglia and tumour cells being in very close proximity to
one another (Figure 2). Whilst GFAP-positive tumour cells
were concentrated in the periphery of the cell clusters,
microglia were found at the core of the cluster (Figure 2).
P2X7R is over-expressed in microglia found in human
glioma cultures
Cell in these clusters were also found to express P2X7R
(Figure 3). The expression of P2X7R was noted in both
tumour cells (Figure 3A,B) and microglia (Figure 3C,D).
Microglia derived from tumour tissue showed higher
levels of P2X7R protein expression than microglia derived
from ‘peri-tumour’ tissue (Figure 4A). Conversely, tumour
cells derived from the core of the glioma were found to
have lower P2X7R expression than tumour cells from
‘peri-tumour’ tissue (Figure 4B).
The pore capacity of P2X7R is active in human glioma
associated microglia
The incorporation of YOPRO-1, a high molecular weight
fluorescence dye, indicates the presence of active P2X7R
pores in human glioma microglia (Figure 5). YOPRO-1
incorporation was inhibited by blocking P2X7R activity
with a specific and irreversible antagonist, oxATP, con-
firming the response was P2X7R specific (Figure 5). A
significantly higher level of YOPRO-1 was incorporated
into the nuclei of the glioma microglia suggesting that
pore activity may be having a similar pro-activation
(trophic) role to that previously described in rat hippo-
campal microglia [4,27].
Inhibition of P2X7R activity was found to lead to a
decrease in the number of tumour cells
When glioma cultures were incubated with BBG (an an-
tagonist of P2X7R) after 3 and 5 days in culture, there
Figure 1 Human glioma cultures. A: Cell clusters (arrow) noted in
glioma cultures. GFAP (red) and DAPI (blue). Arrowhead showing
evidence of nuclear atypia. Scale 100 μM. B: Glioma cultures labeled
with GFAP (Red) showing the highly heterogeneous morphology of
these cells. Scale 20 μm. C: Microglia also formed clusters in glioma
cultures. Red =microglial marker, isolectin GS-IB4. Scale 50 μm.
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of glioma cells in culture by day 10 (Figure 6).
Discussion
Human brain tumours grown in culture comprise micro-
glia that are dispersed throughout and within the core of
the tumour cells. Here we showed that both microglia and
tumour cells expressed P2X7R, with higher expression
levels in microglia associated with the tumour when com-
pared to the ‘peri-tumour’. Importantly, P2X7R pore activ-
ity was evident in tumour-associated microglia. Inhibition
of overall P2X7R function led to a decrease in tumour cell
number, revealing P2X7R as a potential anti-tumour
therapeutic candidate.
In the culture environment, human brain tumours were
found to have a significant number of microglia in close
association with the tumour cells. Microglia within astro-
cytomas are known to proliferate along the architecture
formed by tumour cells [28]. In addition, astrocytoma cells
produce the microglia and monocyte chemoattractant
proten-1 (MCP-1) [29] with microglia expressing the
MCP-1 receptor, CCR2 [30]. Hence, increased presence of
microglia at the site of astrocytic glioma may result from
recruitment of microglia, as well as local microglial prolif-
eration. Interestingly, tumours with a higher proliferation
rate such as GBM contain significantly higher numbers of
activated microglia compared to tumours of lower grade
[2]. Similarly, a positive correlation has been found be-
tween the number of CD11b-positive microglia/macro-
phages in gliomas and the proliferative capacity of the
tumour as indexed by bromodeoxyuridine (BrdU)+ or Ki-
67+ labelling [31]. The proliferative capacity of microglia
within human brain tumours should therefore be taken
into account when histologically characterizing tumour
progression/invasion and potentially determining patient
prognosis.
Interestingly, we found P2X7R expression to be en-
hanced in ‘peri-tumour’ glioma cells compared to tumour-
associated glioma cells, suggesting that this may play a role
actively invading glioma cells. Conversely, P2X7R expres-
sion was increased in tumour-associated microglia com-
pared to microglia derived from the ‘peri-tumour’ brain.
P2X7R up-regulation has been shown in many different
cancer types, but the majority of these studies have not de-
fined the locality (i.e., tumour or ‘peri-tumour’ region) of
that expression. Whether P2X7R functions as a pro-
apoptotic/cytolytic entity or conversely leads to tumour
growth is also not fully understood. There are observa-
tions of enhanced P2X7R expression in solid epithelial tu-
mours [12] and strong up-regulation of P2X7R in samples
from thyroid cancer lines [32]. P2X7R up-regulation was
also shown in thyroid papillary cancer, and the receptor
was found to be fully functional [32], the authors suggest-
ing P2X7R as a possible biomarker of the disease. In
Figure 2 The cell clusters evident in human glioma cultures consisted of glioma cells and microglia. (A to K) Consecutive z-slices of the
cell cluster, each image (slice) taken at 15 μm from the top of the cluster to the bottom. Microglia (isolectin GS-IB4 positive, red) formed the core
of the cluster surrounded by glioma cells (GFAP positive, green). Scale, 50 μm.
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a monoclonal anti-P2X7R antibody is currently being de-
signed for use as a prostate cancer biomarker. Similarly, in
newly diagnosed pediatric acute leukemias P2X7R expres-
sion was increased, especially in cases of relapsed disease
and the receptor was found to be fully functional [34]. In
rat C6 glioma cells P2X7R mRNA and protein were up-
regulated upon exposure to P2X7R specific agonist BzATP,
and the stimulation of P2X7R was linked to release of pro-
inflammatory markers and tumour cell migration [35].
P2X7R stimulation with ATP was found to be important in
maintenance of survival of Neuro-2a neuroblastoma cells
[36]. In neuroblastoma cells, stimulation of P2X7R resulted
in cell shrinkage and plasma membrane blebbing, with no
signs of apoptosis or necrosis, but with evidence of prolifer-
ation [18]. Similarly, immunohistochemical data revealed
increased P2X7R expression in Schwann cells from human
lingual nerve neuromas [37] and in human gliomas [19]. In
this latter study P2X7R expression in glioma tissue was
compared with brain tissue from individuals with other
neurological conditions. No distinction could be madebetween tumour and ‘peri-tumour’ tissue within the same
individual and the specific cell contributions (microglia ver-
sus glioma cells) in the increased P2X7R expression was
also not defined [19].
So while we have shown that microglia occur in close
association to human brain tumour cells and that they
have increased P2X7R expression, do microglia and
P2X7R actually contribute to tumour growth/prolifera-
tion? In primary hippocampal cultures we have previously
shown that P2X7R pore activity (not channel) drives
microglial activation and proliferation as well as inducing
the release of inflammatory mediators [4]. This finding
was somewhat surprising given that this conductance
state of the P2X7R was widely held to be cytolytic
[20,21,24,38-40] rather than trophic. Similarly, in B-cell
chronic lymphocytic leukemia where P2X7R was shown
to be over-expressed, the authors suggested that the re-
ceptor must be non-functional producing an anti-
apoptotic effect and leading to accumulation of tumour
cells [24]. In C6 glioma cell line P2X7R suppression was
also shown to cause cell proliferation with angiogenesis,
Figure 3 The human glioma cell clusters in culture were P2X7R positive. A: Cell cluster of glioma cells (GFAP positive, red) also expressed
P2X7R receptor (green). Scale, 100 μm. B: Magnified image of a glioma cell (GFAP positive, red), also expressing P2X7R (green). Image in the right
showing the co-localization of GFAP and immunoreactivity for P2X7R. Scale, 50 μm. C: Cell cluster in human glioma culture labeled for microglia
(isolectin GS-IB4, red), also showed P2X7R immunoreactivity (green). Scale, 50 μm. D: Magnified image of a microglia (isolectin GS-IB4 positive, red)
showing expression of P2X7R (green). Right image shows co-localization of isolectin GS-IB4 and P2X7R immunoreactivity. Scale, 10 μm.
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receptor [41]. Again, in this study no distinction was
made between P2X7R pore versus channel activity. In
contrast, we found glioma-associated microglia to have
P2X7R pore, which was functional. Unlike the current
dogma, it is possible that P2X7R pore has a trophic ra-
ther than apoptotic role in gliomas.
The current treatment options available for human
high-grade astrocytoma include maximal safe surgicalresection followed by radiotherapy with or without
chemotherapy. However, although aggressive manage-
ment can extend life, there is no cure and there re-
mains a prognostic period of approximately six to
twelve months especially for high-grade tumours [42].
The addition of targeted agents has received intense
interest recently. The role of chemotherapy or radio-
therapy alone remains limited [43,44]. Hence, more ef-
fective treatment modalities are needed. BBG is an
Figure 4 Expression of P2X7R in tumour versus ‘peri- tumour’.
P2X7R expression was measured using immunohistochemistry
against P2X7R protein. The degree of fluorescence intensity
(standardized to background fluorescence intensity) in each cell was
used as an indication of P2X7R expression. A. P2X7R expression was
increased in microglia derived from tumour versus ‘peri-tumour’
tissue. n = 517 cells from 4 human glioma (tumour) and respective
‘peri-tumour’ tissue. Insets above the graph show representative
images of microglia expressing P2X7R. Red =microglial marker
isolectin GS-IB4. Green = P2X7R expression. Scale bar, 20 μm. B.
P2X7R expression was conversely increased in ‘peri-tumour’ glioma
cells compared to glioma cells derived from the core of the tumour. n
= 551 cells from 3 human glioma tumour and respective ‘peri-tumour’
tissue. Insets above the graph show representative images of glioma
cells expressing P2X7R. Red = glioma cell marker, GFAP, Green = P2X7R
expression. Scale bar, 20 μm.
Figure 5 Microglia from human glioma at 3 days post culturing
showed P2X7R pore activity, as evidenced by dye uptake
experiments. YOPRO-1 nuclear intensity was measured as an index of
P2X7R pore capacity (n = 42 microglia being isolectin GS-IB4 positive
from 3 human gliomas). This pore capacity was reduced with inhibition
with a specific and irreversible antagonist of P2X7R, oxATP (250 μM of
oxATP for 3 hours prior to YOPRO-1 incubation, n = 28 microglia, being
isolectin GS-IB4 positive from 3 human gliomas).
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which is a synthetic dye approved by the Food and
Drug Administration as a food additive considered as
one of the safest dyes currently available, with no tox-
icity at doses of up to 12 mg/kg per day in healthy ani-
mals [45]. BBG is also a commonly used synthetic
antagonist of P2X7R [46] with the capacity to pene-
trate the blood brain barrier [26]. In an animal model,
average tissue concentrations of 9.94 - 43.49 μM BBG
administered reduced microglial activation and im-
proved recovery after spinal cord injury [26]. No ad-
verse effects on behaviour, weight, survival, or other
physiological parameters, including body temperature,
blood pH, blood gases, or blood pressure were ob-
served. On this basis, we used even a lower (presum-
ably ‘safer’) dose of BBG (7 μM) that was found to be
effective in decreasing the number of microglia and
glioma cells. It is possible that BBG acts either directly
on P2X7Rs expressed on tumour cells, or indirectly via
inhibiting P2X7Rs on tumour-associated microglia.
We have shown over-expression of P2X7R alone to be
sufficient in inducing microglial activation and prolif-
eration [4]. Once activated, microglia are known to
release factors such as vascular endothelial growth fac-
tor (VEGF) [47] and other cytokines (i.e., including IL-
6 and TNF-α) involved in angiogenesis and tumour
cell migration [48-50]. By driving microglial activation
and proliferation with concomitant release of bioactive
tumorigenic factors, it can be postulated that P2X7R
plays a key role in the molecular hierarchy of glioma
development.
Figure 6 Inhibition of P2X7R with BBG reduced the number of glioma cells and microglia in human glioma cultures. Representative
human glioma cell cultures before (A. control) and after (B. BBG) treatment with brilliant blue G. Red = isolectin GS IB4. Blue = DAPI nuclear stain.
Scale bar, 20 μm. C. Treatment of human glioma cultures with 7 μM BBG at day 3 and day 5 post culture reduced the number of microglial cells.
The number of microglia were counted using immunohistochemistry against a microglial marker, isolectin GS IB4 at 10 days after culturing.
Nuclei were counter labeled with DAPI nuclear stain. Cell numbers were counted using MetaMorph imaging software. n = 109 randomly selected
fields from 3 human gliomas that were not treated with BBG (control). n = 107 randomly selected fields from 3 human gliomas that were treated
with BBG (BBG treated). D. Treatment of human glioma cultures with 7 μM BBG at day 3 and day 5 post culture reduced the number gliomas cells.
The number of glioma cells were counted using immunohistochemistry against GFAP at 10 days after culturing. Nuclei were counter labeled with DAPI
nuclear stain. Cell numbers were counted using MetaMorph imaging software. n = 114 randomly selected fields from 7 human gliomas that were not
treated with BBG (control). n = 113 randomly selected fields from 7 human gliomas that were treated with BBG (BBG treated).
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In conclusion, this study reveals human glioma cultures
to show large numbers of microglia in close association
with tumour cells. Both microglia and the tumour cells
were found to express P2X7R whose expression was
greater in tumour associated microglia versus ‘peri-
tumour’ tissue. Importantly, P2X7R pore was active in
these microglia, and inhibition of P2X7R function re-
sulted in a decrease in the number of glioma cells. Over-
all, our data support P2X7R antagonism as a potential
therapeutic avenue for treatment of human gliomas.Abbreviations
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